Showing 2091-2100 of 5909 results for "".
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Hanita Lenses Announces Launch of Intensity IOLhttps://modernod.com/news/hanita-lenses-announces-launch-of-intensity-iol/2478082/After 3 years of development, Israel-based Hanita Lenses announced the launch of the Intensity IOL. The Intensity is a presbyopia-correcting IOL that has been developed by employing a proprietary iterative algorithm—called the Dynamic Light Utilization (DLU) technology—for better light eff
- Norlase Announces CE Mark Approval for LEAF Green Laserhttps://modernod.com/news/norlase-announces-ce-mark-approval-for-leaf-green-laser/2478045/Norlase announced that it has been granted the CE Mark approval for the LEAF, a first in class, fiberless green laser for the treatment of retina and glaucoma diseases. The CE Mark follows the recent FDA 510(k) market clearance of the LEAF and ISO 13485:2016 certification of Norlase’s medical dev
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- Santen and NTC Announce Positive Outcome of European Decentralised Procedure (DCP) for Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-and-ntc-announce-positive-outcome-of-for-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2477944/Santen EMEA and NTC, have announced the completion and positive outcome of the European Decentralised Procedure (DCP) for a fixed dose combination of levofloxacin and dexamethasone (Ducressa), offering reduced exposure to antibiotics following cataract surgery.1 Levofloxacin is a broa
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- Bausch + Lomb Receives FDA Clearance for Infuse Daily Disposable Silicone Hydrogel Contact Lenseshttps://modernod.com/news/bausch-lombs-infuse-daily-disposable-silicone-hydrogel-contact-lenses-receive-fda-510k-clearance-for/2477862/Bausch + Lomb has received 510(k) clearance from the FDA for the Bausch + Lomb Infuse daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Infuse contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet need
- CMS Increases Penalties Following Nearly 26K COVID-19 Nursing Home Deathshttps://modernod.com/news/cms-increases-penalties-following-nearly-26k-covid-19-nursing-home-deaths/2477852/The Trump administration has increased enforcement of states and nursing homes that have been repeat offenders for not following infection control practices, according to a FierceHealthcare
- Mynosys Changes Name to Centricity Vision; Names New Leadership Teamhttps://modernod.com/news/mynosys-changes-name-to-centricity-vision-names-new-leadership-team/2477834/Centricity Vision, formerly known as Mynosys Cellular Devices, announced a new executive leadership team, along with a new company name. Centricity Vision reflects the company’s core competency, embodied by its Zepto Precision Cataract Surgery Platform, in creating precise, consistent, vis
